Targeting the LIGHT-HVEM Pathway

  • Carl F. Ware
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 647)


Tumor necrosis factor (TNF)-related cytokines function as key communication systems between cells of the immune system and mediate inflammation and tissue destruction. LIGHT (TNFSF14) is a key component of the communication system that controls the responses of T-Cells. LIGHT activates two cell surface receptors, the Herpesvirus Entry Mediator (HVEM) and the Lymphotoxin-β Receptor and is inhibited by soluble decoy receptor-3. The LIGHT-HVEM pathway is an important cosignaling pathway for T-Cells, whereas LIGHT-LTβR modifies the functions of dendritic cells and stromal cells by creating tissue microenvironments, which promote immune responses. HVEM also binds an Ig superfamily member, B and T lymphocyte attenuator (BTLA) that inhibits T-Cell activation. Thus, HVEM serves as a molecular switch between stimulatory and inhibitory signaling. Studies in humans and experimental animal models reveal that LIGHT contributes to inflammation and pathogenesis in mucosal, hepatic, joint and vascular tissues. LIGHT is accessible to biologic-based therapeutics, which can be used to target this molecule during inflammation-driven diseases.


Tumor Necrosis Factor Major Histocompatibility Complex Tumor Necrosis Factor Inhibitor Tumor Necrosis Factor Family Tumor Necrosis Factor Superfamily 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Locksley RM, Killeen N, Lenardo MJ The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001; 104:487–501.PubMedCrossRefGoogle Scholar
  2. 2.
    Feldmann M, Brennan FM, Paleolog E et al. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease? Novartis Found Symp 2004; 256:53–69; discussion 69–73, 106–111, 266–109.PubMedCrossRefGoogle Scholar
  3. 3.
    Granger SW, Ware CF. Commentary: Turning on LIGHT. J Clinical Investigation 2001; 108:1741–1742.Google Scholar
  4. 4.
    Watts TH. TNF/TNFR family members in costimulation of T-Cell responses. Annu Rev Immunol 2005; 23:23–68.PubMedCrossRefGoogle Scholar
  5. 5.
    So T, Lee SW, Croft M. Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity. Int J Hematol 2006; 83(1):1–11.PubMedCrossRefGoogle Scholar
  6. 6.
    Ware CF. NETWORK COMMUNICATIONS: Lymphotoxins, LIGHT and TNF. Annu Rev Immunol 2005; 23:787–819.PubMedCrossRefGoogle Scholar
  7. 7.
    Chaplin D, Fu YX. Cytokine regulation of secondary lymphoid organ development. Curr Opin Immunol 1998; 10:289–297.PubMedCrossRefGoogle Scholar
  8. 8.
    Gommerman JL, Browning JL. Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol, 2003; 3(8):642–655.PubMedCrossRefGoogle Scholar
  9. 9.
    Drayton DL, Liao S, Mounzer RH, Ruddle NH. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol 2006; 7(4):344–353.PubMedCrossRefGoogle Scholar
  10. 10.
    Mauri DN, Ebner R, Montgomery RI et al. LIGHT, a new member of the TNF superfamily and lymphotoxin a are ligands for herpesvirus entry mediator. Immunity 1998; 8:21–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Rooney IA, Butrovich KD, Glass AA et al. The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J Biol Chem 2000; 275:14307–14315.PubMedCrossRefGoogle Scholar
  12. 12.
    Yu KY, Kwon B, Ni J et al. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 1999; 274(20):13733–13736.PubMedCrossRefGoogle Scholar
  13. 13.
    Sedy JR, Gavrieli M, Potter KG et al. B and T-lymphocyte attenuator regulates T-Cell activation through interaction with herpesvirus entry mediator. Nat Immunol 2005; 6(1):90–98.PubMedCrossRefGoogle Scholar
  14. 14.
    Compaan DM, Gonzalez LC, Tom et al. Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex. J Biol Chem 2005; 280(47):39553–39561.PubMedCrossRefGoogle Scholar
  15. 15.
    Garapati VP, Lefranc MP. IMGT Colliers de Perles and IgSF domain standardization for T-Cell costimulatory activatory (CD28, ICOS) and inhibitory (CTLA4, PDCD1 and BTLA) receptors. Dev Comp Immunol 2007.Google Scholar
  16. 16.
    Keir ME, Sharpe AH. The B7/CD28 costimulatory, family in autoimmunity. Immunol Rev 2005; 204:128–143.PubMedCrossRefGoogle Scholar
  17. 17.
    Riley JL, June CH. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 2005; 105(1):13–21.PubMedCrossRefGoogle Scholar
  18. 18.
    Chemnitz JM, Lanfranco AR, Braunstein I et al. B and T-lymphocyte attenuator-mediated signal transduction provides a potent inhibitory signal to primary human CD4 T-Cells that can be initiated by multiple phosphotyrosine motifs. J Immunol 2006; 176(11):6603–6614.PubMedGoogle Scholar
  19. 19.
    Wu TH, Zhen Y, Zeng C et al. B and T-lymphocyte attenuator interacts with CD3zeta and inhibits tyrosine phosphorylation of TCRzeta complex during T-cell activation. Immunol Cell Biol 2007.Google Scholar
  20. 20.
    Cheung TC, Humphreys IR, Potter KG et al. Evolutionarily divergent herpesviruses modulate T-Cell activation by targeting the herpesvirus entry mediator cosignaling pathway. Proc Natl Acad Sci USA 2005; 102(37):13218–13223.PubMedCrossRefGoogle Scholar
  21. 21.
    Croft M. The evolving crosstalk between co-stimulatory and co-inhibitory receptors: HVEM-BTLA. Trends Immunol 2005; 26(6):292–294.PubMedCrossRefGoogle Scholar
  22. 22.
    Watts TH, Gommerman JL. The LIGHT and DARC sides of herpesvirus entry mediator. Proc Natl Acad Sci USA 2005; 102(38):13365–13366.PubMedCrossRefGoogle Scholar
  23. 23.
    Kabashima K, Banks TA, Ansel KM et al. Intrinsic lymphotoxin-beta receptor requirement for homeostasis of lymphoid tissue dendritic cells. Immunity 2005; 22(4):439–450.PubMedCrossRefGoogle Scholar
  24. 24.
    Scheu S, Alferink J, Potzel T et al. Targeted Disruption of LIGHT Causes Defects in Costimulatory T-Cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J Exp Med 2002; 195:1613–1624.PubMedCrossRefGoogle Scholar
  25. 25.
    Tamada K, Ni J, Zhu G et al. Cutting Edge: Selective Impairment of CD8(+) T-Cell Function in Mice Lacking the TNF Superfamily Member LIGHT. J Immunol 2002; 168(10):4832–4835.PubMedGoogle Scholar
  26. 26.
    Liu J, Schmidt CS, Zhao F et al. LIGHT-deficiency impairs CD8+ T-Cell expansion, but not effector function. Int Immunol 2003; 15(7):861–870.PubMedCrossRefGoogle Scholar
  27. 27.
    Rennert P, Browning JL, Hochman PS. Normal development of lymphnodes is disrupted by soluble, LT beta receptor-Ig fusion, protein. Europe Cytokine Network 1996; 7.Google Scholar
  28. 28.
    Nishikawa S, Honda K, Vieira P. Organogenesis of peripheral lymphoid organs. Immunol Rev 2003; 195:72–80.PubMedCrossRefGoogle Scholar
  29. 29.
    Mackay F, Browning JL, Lawton P et al. Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis. Gastroenterology 1998; 115(6):1464–1475.PubMedCrossRefGoogle Scholar
  30. 30.
    Anand S, Wang P, Yoshimura K et al. Essential role, of TNF family molecule LIGHT as a cytokine in the pathogenesis of hepatitis. J Clin Invest 2006; 116(4):1045–1051.PubMedCrossRefGoogle Scholar
  31. 31.
    Rahman MM, McFadden G. Modulation of tumor necrosis factor by microbial pathogens. PLoS Pathog 2006; 2(2):e4.PubMedCrossRefGoogle Scholar
  32. 32.
    Smith CA, Davis T, Anderson D et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins Science 1990; 248:1019–1024.PubMedCrossRefGoogle Scholar
  33. 33.
    Kinkade A, Ware CF. The DARC conspiracy—virus invasion tactics. Trends Immunol 2006; 27(8):362–367.PubMedCrossRefGoogle Scholar
  34. 34.
    Sedgmen BJ, Dawicki W, Gommerman JL et al. LIGHT is dispensable for CD4+ and CD8+ T-Cell and antibody responses to influenza A virus in mice. Int Immunol 2006; 18(5):797–806.PubMedCrossRefGoogle Scholar
  35. 35.
    Banks TA, Rickert S, Benedict CA et al. A-lymphotoxin-IFN-beta axis essential for lymphocyte survival revealed during cytomegalovirus infection. J Immunol 2005; 174(11):7217–7225.PubMedGoogle Scholar
  36. 36.
    Cohavy O, Zhou J, Granger SW et al. LIGHT expression by mucosal T-Cells may regulate IFN-gamma expression in the intestine. J Immunol 2004; 173(1):251–258.PubMedGoogle Scholar
  37. 37.
    Cohavy O, Zhou J, Ware CF et al. LIGHT is constitutively expressed on T and NK cells in the human gut and can be induced by CD2-Mediated signaling. J Immunol 2005; 174(2):646–653.PubMedGoogle Scholar
  38. 38.
    Rioux JD, Silverberg MS, Daly MJ et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet 2000; 66:1863–1870.PubMedCrossRefGoogle Scholar
  39. 39.
    Low JH, Williams FA, Yang X et al. Inflammatory bowel disease is linked to 19p13 and associated with ICAM-1. Inflamm Bowel Dis 2004; 10(3):173–181.PubMedCrossRefGoogle Scholar
  40. 40.
    Tello-Ruiz MK, Curley C, DelMonte T et al. Haplotype-based association analysis of 56 functional candidate genes in the, IBD6 locus on chromosome 19. Eur J Hum Genet 2006; 14(6):780–790.PubMedCrossRefGoogle Scholar
  41. 41.
    Scholz H, Sandberg W, Damas JK et al. Enhanced plasma levels of LIGHT in unstable angina: possible pathogenic role in foam cell formation and thrombosis. Circulation 2005; 112(14):2121–2129.PubMedCrossRefGoogle Scholar
  42. 42.
    Kosuge H, Suzuki JI, Kakuta T et al. Attenuation, of graft arterial disease by manipulation of the LIGHT Pathway. Arterioscler Thromb Vasc Biol 2004.Google Scholar
  43. 43.
    Padovani JC, Pazin-Filho A, Simoes MV. Gene polymorphisms in the TNF locus and the risk of myocardial infarction. Thromb Res 2000; 100(4):263–269.PubMedCrossRefGoogle Scholar
  44. 44.
    Tanaka T, Ozaki K. Inflammation as a risk factor for myocardial infarction. J Hum Genet 2006; 51(7):595–604.PubMedCrossRefGoogle Scholar
  45. 45.
    Clarke R, Xu P, Bennett D et al. Lymphotoxin-alpha gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS case-control study. PLoS Genet 2006; 2(7):e107.PubMedCrossRefGoogle Scholar
  46. 46.
    Lo JC, Wang Y, Tumanov AV et al. Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science 2007; 316(5822):285–288.PubMedCrossRefGoogle Scholar
  47. 47.
    Edwards JR, Sun SG, Locklin R et al. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. Arthritis Rheum 2006; 54(5):1451–1462.PubMedCrossRefGoogle Scholar
  48. 48.
    Shaikh R, Santee S, Granger SW et al. Constitutive expression of LIGHT on T-Cells leads to lymphocyte activation, inflammation and tissue destruction. J Immunol 2001; 167:6330–6337.PubMedGoogle Scholar
  49. 49.
    Wang J, Lo JC, Foster A et al. The regulation of T-Cell homeostasis and autoimmunity by T-Cell derived LIGHT. J Clin Invest 2001; 108:1771–1780.PubMedGoogle Scholar
  50. 50.
    Wang J, Anders RA, Wang Y et al. The critical role of LIGHT in promoting intestinal inflammation and Crohn’s disease. J Immunol 2005; 174(12):8173–8182.PubMedGoogle Scholar
  51. 51.
    Fan Z, Yu P, Wang Y et al. NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood 2006; 107(4):1342–1351.PubMedCrossRefGoogle Scholar
  52. 52.
    Brown GR, Lee EL, El-Hayek J et al. IL-12-independent LIGHT signaling enhances MHC class II disparate CD4+ T-Cell alloproliferation, IFN-gamma responses and intestinal graft-versus-host disease. J Immunol 2005; 174(8):4688–4695.PubMedGoogle Scholar
  53. 53.
    Wu Q, Fu YX, Sontheimer RD. Blockade of lymphotoxin signaling inhibits the clinical expression of murine graft-versus-host skin disease. J Immunol 2004; 172(3):1630–1636.PubMedGoogle Scholar
  54. 54.
    Gommerman JL, Giza K, Perper S et al. A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT. J Clin Invest 2003; 112(5):755–767.PubMedGoogle Scholar
  55. 55.
    Plant SR, Iocca HA, Wang Y et al. Lymphotoxin beta receptor (Lt betaR): dual roles in demyelination and remyelination and successful therapeutic intervention using Lt betaR-Ig protein. J Neurosci 2007; 27(28):7429–7437.PubMedCrossRefGoogle Scholar
  56. 56.
    Fava RA, Notidis E, Hunt J et al. A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis. J Immunol 2003; 171(1):115–126.PubMedGoogle Scholar
  57. 57.
    Ye Q, Fraser CC, Gao W et al. Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival. J Exp Med 2002; 195(6):795–800.PubMedCrossRefGoogle Scholar
  58. 58.
    Xu Y, Flies AS, Flies DB et al. Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease. Blood 2007; 109(9):4097–4104.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  • Carl F. Ware
    • 1
  1. 1.Division of Molecular ImmunologyLa Jolla Institute for Allergy and ImmunologyLa JollaUSA

Personalised recommendations